Program 02: Gynecologic Cancers

妇科癌症项目 项目总结/摘要 妇科（Gyn）癌症项目的使命是通过开发新的 通过跨学科的综合转化研究，制定早期发现、治疗和预防战略。 财团一个相关的使命是培养和教育下一代的翻译研究人员，临床 试验者、结果研究者和专注于妇科癌症的基础科学家。该方案包括 调查所有妇科癌症，包括卵巢癌、子宫内膜癌、宫颈癌、阴道癌、外阴癌和生殖细胞癌 以及妊娠滋养细胞疾病。此外，我们应对子宫内膜异位症的发病率不断增加， 癌症（EnCa）在我们的集水区（马萨诸塞州）以及种族差异的诊断和治疗 子宫颈癌和EnCa在马萨诸塞州。 上一次CCSG更新（2016年）中未包括先前的妇科癌症DF/HCC计划;当前 程序被彻底修改。它的59名成员（47名初级成员和12名次级成员）代表5个DF/HCC 学院和6个学术部门。2019年，该计划的同行评审赠款资金为 210万美元的直接费用来自NCI，120万美元来自其他赞助商。在目前的资金 在此期间，主要项目成员发表了629篇与癌症相关的论文。其中，20%是在... 在机构合作方面，27%是方案内合作，34%是两个或两个以上机构之间的方案间合作。 更多DF/HCC成员。 在下一个CCSG资助期内，该计划的具体目标是：1）尽早制定和实施 马萨诸塞州及其他地区妇科癌症的检测、预防、诊断和预后方法 美国; 2）开发和推进妇科癌症的新治疗策略; 3）教育和指导 通过奖学金计划，初级教师发展， 在国家委员会中安排初级教员。这些目标与总部大楼/总部合同委员会战略计划完全一致 需要CCSG的全套组件：共享资源、协作基础设施、有效的 临床试验审查和实施系统，以及社区参与和癌症的结构化流程 研究训练。

Gynecologic Cancers Program Project Summary / Abstract The mission of the Gynecologic (Gyn) Cancers Program is to improve patient outcomes by developing novel strategies for early detection, therapy, and prevention through integrated translational research across the consortium. A related mission is to train and educate the next generation of translational researchers, clinical trialists, outcomes researchers, and basic scientists who focus on Gyn cancers. The Program encompasses investigation of all Gyn cancers including ovarian, endometrial, cervical, vaginal, vulvar, and germ cell cancers as well as gestational trophoblastic disease. Moreover, we respond to the increasing incidence of endometrial cancer (EnCa) in our catchment area (Massachusetts) as well as racial disparities in diagnosis and treatment of cervical cancer and EnCa in Massachusetts. A previous DF/HCC Program in Gyn Cancers was not included in the last CCSG renewal (2016); the current Program is thoroughly revamped. Its 59 members (47 primary and 12 secondary) represent five DF/HCC institutions and 6 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was $2.1 million in direct costs from the NCI and $1.2 million from other sponsors. During the current funding period, primary Program members published 629 cancer-relevant papers. Of these, 20% were inter- institutional, 27% were intra-programmatic, and 34% were inter-programmatic collaborations between two or more DF/HCC members. For the next CCSG funding period, the Program’s Specific Aims are to: 1) Develop and implement early detection, prevention, diagnostic, and prognostic methods for Gyn cancers in Massachusetts and across the US; 2) Develop and advance novel therapeutic strategies for Gyn cancers; and 3) Educate and mentor the next generation of leaders for Gyn Cancers through fellowship programs, junior faculty development, and placement of junior faculty on national committees. These goals align perfectly with the DF/HCC strategic plan and will require the full suite of CCSG components: shared resources, collaborative infrastructure, an effective system for clinical trial review and conduct, and structured processes for community engagement and cancer research training.